Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of SEL120 in Acute Myeloid Leukemia Patients

Trial Profile

A Phase I Study of SEL120 in Acute Myeloid Leukemia Patients

Phase of Trial: Phase I

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs SEL-120 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Apr 2018 New trial record
    • 06 Apr 2018 According to Selvita media release, trial is expected to start in 1Q2019
    • 08 Aug 2017 According to a Selvita media release, Selvita and The Leukemia and Lymphoma Society have entered a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients with acute myeloid leukemia.Under the terms of the agreement, LLS will provide up to 3.25 dollar million funding over 4 years, through its Therapy Acceleration Program in order to help fund further SEL120 IND-enabling studies and this phase I trial in acute myeloid leukemia patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top